Studies have shown that for patients with pCCA and dCCA, changes in the immune status of tumor tissue after radiotherapy are related to the effect of treatment, and patients with higher lymphocyte expression levels of PD-L1 and CD8+ cytotoxins in tumor tissues before and after combined chemoradiotherapy have a poor prognosis (39). The gene discussed is CD8A; the disease is neoplasm.